Objective To study the clinical characteristics and outcome of Pneumocystis carinii pneumonia(PCP) in patients with chronic kidney diseases.Methods Clinical data of 8 cases of chronic kidney diseases complicated with ...Objective To study the clinical characteristics and outcome of Pneumocystis carinii pneumonia(PCP) in patients with chronic kidney diseases.Methods Clinical data of 8 cases of chronic kidney diseases complicated with PCP(excluding renal transplant patients) were examined retrospectively.Results The most common presenting symptoms at admission were fever(100%),cough without or with a little sputum(87.5%),and exertional dyspnea(75%).Beside these,they complained of chest tightness,fatigue,sweating and chills.Six patients(75%) presented with hypoxemia were diagnosed with type 1 respiratory failure during the course of illness.The most common CT feature was bilateral patchy areas of ground-glass opacities.Five patients had peripheral blood lymphocyte count less than 1 ×109/L.Four patients had CD4 cell count less than 200/mm3.Serum LDH level was elevated in 5 patients(582±222.55).Among the 8 patients,2 patients died within 20 days of PCP diagnosis.Conclusion Pneumocystis carinii pneumonia is an opportunistic and serious complication in chronic kidney disease patients treated with immunosuppressants.The disease progression is fast and patients with respiratory failure have a high mortality rate.Early diagnosis and appropriate treatment are important for better prognosis.展开更多
Objective:To investigate the clinical features of R-CHOP regimen in the treatment of non-Hodgkin^lymphoma with Pneumocystis carinii pneumonia(PCP)in order to improve the understanding of PCP and the side effects of Ri...Objective:To investigate the clinical features of R-CHOP regimen in the treatment of non-Hodgkin^lymphoma with Pneumocystis carinii pneumonia(PCP)in order to improve the understanding of PCP and the side effects of Rituxan.Methods:A retrospective analysis of 90 patients with non-Hodgkin’s lymphoma treated with R-CHOP chemotherapy in our hospital from November 2015 to November 2020,of which 15(16.7%)patients,combined with PCP clinical data,including clinical symptoms,physical signs,chest imaging examination and treatment data were used for to analysis and summarization.Results:The clinical features of R-CHOP chemotherapy combined with PCP were fever,cough,and sputum.Some patients had fewer clinical symptoms.Common imaging manifestations were double lung membrane glass shadow,patchy shadow,and flocculent shadow.It can occur in all clinical stages,and the incidence of late stage is high,and there is no clear correlation with bone marrow suppression.Pneumocystis was found in 2 cases of sputum,and the rest of the patients were clinically diagnosed.The main therapeutic drugs are sulfamethoxazole(8/15),compound sulfamethoxazole(6/15),clindamycin(1/15,sulfa drug allergy),and adrenal cortex hormones(4/15).Fourteen cases were cured and 1 case died.Conclusion:The incidence of R-CHOP in advanced non-Hodgkin^lymphoma of PCP is high.Patients with clinical use of R-CHOP chemotherapy will encounter fever,cough,chest computed tomography(CT)film glass shadow,and diffuse patch shadow.Patients should be alert to the possibility of PCP and take sulfonamides as soon as possible for medical treatment.展开更多
Despite advances in transplantation techniques and the quality of post-transplantation care, opportunistic infections remain an important cause of complications. Pneumocystis jirovecii(P. jirovecii) is an opportunisti...Despite advances in transplantation techniques and the quality of post-transplantation care, opportunistic infections remain an important cause of complications. Pneumocystis jirovecii(P. jirovecii) is an opportunistic organism, represents an important cause of infections in heart transplantation patients. Almost 2% to 10% of patients undergoing cardiac transplantation have Pneumocystis pneumonia. Prophylaxis is essential after surgery. Various prophylaxis regimes had been defined in past and have different advantages. Trimethoprim/sulfamethoxazole(TMP/SMX) has a key role in prophylaxis against P. jirovecii. Generally, although TMP/SMX is well tolerated, serious side effects have also been reported during its use. Pentamidine is an alternative prophylaxis agent when TMP/SMX cannot be tolerated by the patient. Structurally, pentamidine is an aromatic diamidine compound with antiprotozoal activity. Since it is not effectively absorbed from the gastrointestinal tract, it is frequently administered via the intravenous route. Pentamidine can alternatively be administered through inhalation at a monthly dose in heart transplant recipients. Although, the efficiency and safety of this drug is well studied in other types of solid organ transplantations, there are only few data about pentamidine usage in heart transplantation. We sought to evaluate evidence-based assessment of the use of pentamidine against P. jirovecii after heart transplantation.展开更多
目的对非艾滋病肺孢子虫肺炎(PCP)患者的临床资料进行分析,总结其临床特点,从而提高临床诊治水平,改善患者预后。方法回顾性分析9例非艾滋病PCP患者的临床表现、实验室检查结果、影像学特征、治疗及转归。结果主要临床表现为发热7例(77....目的对非艾滋病肺孢子虫肺炎(PCP)患者的临床资料进行分析,总结其临床特点,从而提高临床诊治水平,改善患者预后。方法回顾性分析9例非艾滋病PCP患者的临床表现、实验室检查结果、影像学特征、治疗及转归。结果主要临床表现为发热7例(77.8%)、咳嗽6例(66.7%)、喘息4例(44.4%)。胸部CT主要表现为双肺弥漫性或散在斑片影、磨玻璃影及囊状透亮影,斑片影9例(100.0%)、磨玻璃影5例(55.6%)、囊状透亮影5例(55.6%),双肺内、中、外带分布无差异,肋膈角处可累及,合并纵隔淋巴结增大3例(33.3%)、胸腔积液1例(11.1%)。9例患者中,白细胞计数(WBC)升高5例(55.6%),平均WBC(10.53±4.24)×10^(9)/L;降钙素原(PCT)不同程度升高8例(88.9%),平均PCT(0.19±0.18)ng/ml;氧合指数不同程度下降7例(77.8%),平均氧合指数(245.50±140.30)mm Hg(1 mm Hg=0.133 kPa);淋巴细胞计数下降3例(33.3%),平均淋巴细胞计数(1.16±0.61)×10^(9)/L。6例(66.7%)应用复方磺胺甲噁唑(SMZ-TMP)+卡泊芬净治疗,1例(11.1%)单用SMZ-TMP,2例(22.2%)单用卡泊芬净,6例(66.7%)合并应用糖皮质激素。6例(66.7%)患者疗效好,3例(33.3%)患者病情恶化自动出院。结论非艾滋病PCP缺乏特异性临床特点,临床工作中需提高警惕,恶性肿瘤、长期接受激素治疗、糖尿病等免疫受损患者出现发热、咳嗽、喘息等临床症状,加之合并斑片影、磨玻璃影等胸部影像学改变,需及时留取合格下呼吸道标本送检,尽早干预治疗,改善预后。展开更多
文摘Objective To study the clinical characteristics and outcome of Pneumocystis carinii pneumonia(PCP) in patients with chronic kidney diseases.Methods Clinical data of 8 cases of chronic kidney diseases complicated with PCP(excluding renal transplant patients) were examined retrospectively.Results The most common presenting symptoms at admission were fever(100%),cough without or with a little sputum(87.5%),and exertional dyspnea(75%).Beside these,they complained of chest tightness,fatigue,sweating and chills.Six patients(75%) presented with hypoxemia were diagnosed with type 1 respiratory failure during the course of illness.The most common CT feature was bilateral patchy areas of ground-glass opacities.Five patients had peripheral blood lymphocyte count less than 1 ×109/L.Four patients had CD4 cell count less than 200/mm3.Serum LDH level was elevated in 5 patients(582±222.55).Among the 8 patients,2 patients died within 20 days of PCP diagnosis.Conclusion Pneumocystis carinii pneumonia is an opportunistic and serious complication in chronic kidney disease patients treated with immunosuppressants.The disease progression is fast and patients with respiratory failure have a high mortality rate.Early diagnosis and appropriate treatment are important for better prognosis.
文摘Objective:To investigate the clinical features of R-CHOP regimen in the treatment of non-Hodgkin^lymphoma with Pneumocystis carinii pneumonia(PCP)in order to improve the understanding of PCP and the side effects of Rituxan.Methods:A retrospective analysis of 90 patients with non-Hodgkin’s lymphoma treated with R-CHOP chemotherapy in our hospital from November 2015 to November 2020,of which 15(16.7%)patients,combined with PCP clinical data,including clinical symptoms,physical signs,chest imaging examination and treatment data were used for to analysis and summarization.Results:The clinical features of R-CHOP chemotherapy combined with PCP were fever,cough,and sputum.Some patients had fewer clinical symptoms.Common imaging manifestations were double lung membrane glass shadow,patchy shadow,and flocculent shadow.It can occur in all clinical stages,and the incidence of late stage is high,and there is no clear correlation with bone marrow suppression.Pneumocystis was found in 2 cases of sputum,and the rest of the patients were clinically diagnosed.The main therapeutic drugs are sulfamethoxazole(8/15),compound sulfamethoxazole(6/15),clindamycin(1/15,sulfa drug allergy),and adrenal cortex hormones(4/15).Fourteen cases were cured and 1 case died.Conclusion:The incidence of R-CHOP in advanced non-Hodgkin^lymphoma of PCP is high.Patients with clinical use of R-CHOP chemotherapy will encounter fever,cough,chest computed tomography(CT)film glass shadow,and diffuse patch shadow.Patients should be alert to the possibility of PCP and take sulfonamides as soon as possible for medical treatment.
文摘Despite advances in transplantation techniques and the quality of post-transplantation care, opportunistic infections remain an important cause of complications. Pneumocystis jirovecii(P. jirovecii) is an opportunistic organism, represents an important cause of infections in heart transplantation patients. Almost 2% to 10% of patients undergoing cardiac transplantation have Pneumocystis pneumonia. Prophylaxis is essential after surgery. Various prophylaxis regimes had been defined in past and have different advantages. Trimethoprim/sulfamethoxazole(TMP/SMX) has a key role in prophylaxis against P. jirovecii. Generally, although TMP/SMX is well tolerated, serious side effects have also been reported during its use. Pentamidine is an alternative prophylaxis agent when TMP/SMX cannot be tolerated by the patient. Structurally, pentamidine is an aromatic diamidine compound with antiprotozoal activity. Since it is not effectively absorbed from the gastrointestinal tract, it is frequently administered via the intravenous route. Pentamidine can alternatively be administered through inhalation at a monthly dose in heart transplant recipients. Although, the efficiency and safety of this drug is well studied in other types of solid organ transplantations, there are only few data about pentamidine usage in heart transplantation. We sought to evaluate evidence-based assessment of the use of pentamidine against P. jirovecii after heart transplantation.
文摘目的对非艾滋病肺孢子虫肺炎(PCP)患者的临床资料进行分析,总结其临床特点,从而提高临床诊治水平,改善患者预后。方法回顾性分析9例非艾滋病PCP患者的临床表现、实验室检查结果、影像学特征、治疗及转归。结果主要临床表现为发热7例(77.8%)、咳嗽6例(66.7%)、喘息4例(44.4%)。胸部CT主要表现为双肺弥漫性或散在斑片影、磨玻璃影及囊状透亮影,斑片影9例(100.0%)、磨玻璃影5例(55.6%)、囊状透亮影5例(55.6%),双肺内、中、外带分布无差异,肋膈角处可累及,合并纵隔淋巴结增大3例(33.3%)、胸腔积液1例(11.1%)。9例患者中,白细胞计数(WBC)升高5例(55.6%),平均WBC(10.53±4.24)×10^(9)/L;降钙素原(PCT)不同程度升高8例(88.9%),平均PCT(0.19±0.18)ng/ml;氧合指数不同程度下降7例(77.8%),平均氧合指数(245.50±140.30)mm Hg(1 mm Hg=0.133 kPa);淋巴细胞计数下降3例(33.3%),平均淋巴细胞计数(1.16±0.61)×10^(9)/L。6例(66.7%)应用复方磺胺甲噁唑(SMZ-TMP)+卡泊芬净治疗,1例(11.1%)单用SMZ-TMP,2例(22.2%)单用卡泊芬净,6例(66.7%)合并应用糖皮质激素。6例(66.7%)患者疗效好,3例(33.3%)患者病情恶化自动出院。结论非艾滋病PCP缺乏特异性临床特点,临床工作中需提高警惕,恶性肿瘤、长期接受激素治疗、糖尿病等免疫受损患者出现发热、咳嗽、喘息等临床症状,加之合并斑片影、磨玻璃影等胸部影像学改变,需及时留取合格下呼吸道标本送检,尽早干预治疗,改善预后。
